BBVA USA Bancshares’s AstraZeneca AZN Stock Holding History

BBVA USA Bancshares’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,085	Closed	-$254K	–	532
2017 Q1	$254K	Sell	4,085 -11,759	-74%	-$685K	0.02%	494
2016 Q4	$866K	Sell	15,844 -12,513	-44%	-$710K	0.06%	279
2016 Q3	$1.86M	Sell	28,357 -5,549	-16%	-$363K	0.13%	155
2016 Q2	$2.05M	Sell	33,906 -1,480	-4%	-$86K	0.15%	140
2016 Q1	$1.99M	Buy	35,386 +7,058	+25%	+$424K	0.15%	154
2015 Q4	$1.92M	Buy	28,328 +14,680	+108%	+$962K	0.14%	150
2015 Q3	$868K	Buy	13,648 +9,815	+256%	+$646K	0.07%	231
2015 Q2	$244K	Buy	+3,833	New	+$262K	0.01%	468

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BBVA USA Bancshares's AZN Position: Q2 2017 in Review

BBVA USA Bancshares sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 4,085 shares — an estimated $254K sold.

BBVA USA Bancshares first reported a position in AZN in Q2 2015 and held it in 8 quarters. The position peaked at $2.05M in Q2 2016. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

BBVA USA Bancshares reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
BBVA USA Bancshares sold 4,085 AstraZeneca shares in Q2 2017, an estimated $254K.
BBVA USA Bancshares first reported a position in AstraZeneca in Q2 2015 and held it in 8 quarters.
BBVA USA Bancshares's AstraZeneca position peaked at $2.05M in Q2 2016.
466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on BBVA USA Bancshares's 13F filing for Q2 2017, filed 27 Jul 2017.